- Home
- CUE vs SACH Comparison
CUE vs SACH Comparison
Compare CUE & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- SACH
- Stock Information
- Founded
- CUE 2014
- SACH 2010
- Country
- CUE United States
- SACH United States
- Employees
- CUE N/A
- SACH N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- SACH Real Estate Investment Trusts
- Sector
- CUE Health Care
- SACH Real Estate
- Exchange
- CUE Nasdaq
- SACH Nasdaq
- Market Cap
- CUE 61.1M
- SACH 50.6M
- IPO Year
- CUE 2018
- SACH 2017
- Fundamental
- Price
- CUE $0.56
- SACH $0.98
- Analyst Decision
- CUE Strong Buy
- SACH Hold
- Analyst Count
- CUE 2
- SACH 3
- Target Price
- CUE $3.00
- SACH $2.00
- AVG Volume (30 Days)
- CUE 394.8K
- SACH 146.6K
- Earning Date
- CUE 11-12-2025
- SACH 11-05-2025
- Dividend Yield
- CUE N/A
- SACH 20.56%
- EPS Growth
- CUE N/A
- SACH N/A
- EPS
- CUE N/A
- SACH N/A
- Revenue
- CUE $7,100,000.00
- SACH $3,906,000.00
- Revenue This Year
- CUE N/A
- SACH N/A
- Revenue Next Year
- CUE N/A
- SACH $6.63
- P/E Ratio
- CUE N/A
- SACH N/A
- Revenue Growth
- CUE N/A
- SACH N/A
- 52 Week Low
- CUE $0.54
- SACH $0.80
- 52 Week High
- CUE $1.75
- SACH $1.76
- Technical
- Relative Strength Index (RSI)
- CUE 28.56
- SACH 35.42
- Support Level
- CUE $0.57
- SACH $0.96
- Resistance Level
- CUE $0.62
- SACH $1.08
- Average True Range (ATR)
- CUE 0.08
- SACH 0.04
- MACD
- CUE -0.01
- SACH -0.01
- Stochastic Oscillator
- CUE 0.53
- SACH 17.79
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.